Glucagon-Like Peptide-1 Protects Against Atrial Fibrillation and Atrial Remodeling in Type 2 Diabetic Mice

•AF is highly prevalent in type 2 diabetes mellitus where it increases morbidity and mortality.•GLP-1R agonists are used to treat T2DM, but their effects on AF are unclear.•T2DM db/db mice are highly susceptible to AF in association with atrial electrical and structural remodeling.•GLP-1 and liraglutide (GLP-1R agonist) prevented AF as well as atrial remodeling in db/db mice.•GLP-1R agonists may represent a therapeutic option to prevent AF in patients with T2DM.